"Hyundai Motor Company Will Overtake Toyota Motor Corporation in Market Cap," Target Price Raised to 1.2 Million Won, Up 50% ... "Samsung Biologics Has 37% Upside" [Stocktopia]

\r\n
[The Financial News] Here is a roundup of major brokerage reports as of the morning of May 28.
Hyundai Motor Company is expected to expand its long-term earnings base by taking advantage of global rivals' retreat from EV strategies, and on that basis, it is forecast to lead the autonomous driving and humanoid industries.
Samsung Biologics is seen as likely to strengthen its medium- to long-term earnings stability, supported by structural growth in the global contract development and manufacturing organization (CDMO) market and the securing of a North American production base. ICTK is also expected to emerge as a leading domestic quantum industry stock, backed by the Trump administration's support measures for the sector.
\r\n\r\n◆Hyundai Motor Company (005380)— KB Securities / Analyst Kang Sung-jin
- Target price: 1.2 million won (raised 50% from 800,000 won) | Previous close: 681,000 won
- Investment rating: Buy (maintained)
KB Securities raised its target price for Hyundai Motor Company to 1.2 million won, saying the company will become a flagship name in physical AI by expanding long-term profits on the back of global rivals' retreat from EV strategies and by leading the humanoid industry.
Analyst Kang Sung-jin said, "Volkswagen has recognized massive losses due to weak sales and revisions to its EV strategy, and it is considering large-scale layoffs and the sale or lease of factories." He added that Ford and Honda are also facing further losses. By contrast, Hyundai Motor Group is expanding its market share in the United States based on competitive EV platforms and hybrid models, while also defending its share in Europe.
Kang also said, "Boston Dynamics is overwhelmingly ahead in industrial humanoid competitiveness right now," and predicted that "Hyundai Motor Group's market capitalization of 201 trillion won, despite its competitiveness in both its core auto business and future humanoids, will target Toyota Motor Corporation's market cap of 441 trillion won over the medium to long term."※ Physical AIThis refers to AI that goes beyond operating only on screens and instead has a physical body, like robots and cars, moving in the real world. Autonomous vehicles and humanoid robots are prime examples, as they evolve into systems that perceive their surroundings, make decisions on their own, and carry out physical actions.
\r\n\r\n◆Samsung Biologics (207940)— KB Securities / Analyst Shin Ji-hoon
- Target price: 1.9 million won | Previous close: 1.384 million won
- Investment rating: Buy
KB Securities said Samsung Biologics has strong potential for order growth and medium- to long-term earnings expansion, supported by factory expansion and the securing of a production base in the United States, and set a target price of 1.9 million won.
Analyst Shin Ji-hoon said, "Its far higher margins and earnings stability than peers, along with order growth driven by the spin-off of Samsung Bioepis, will support growth."
In particular, the company drew attention for acquiring GSK's Rockville, Maryland plant in March for $353 million and increasing its total production capacity to 845,000 liters. Shin said, "This will help ease tariff risks and improve access to North American customers, contributing to future order growth."
Additional growth drivers were also cited, including revenue contributions from the full-scale operation of Plant 5 and potential spillover benefits if sanctions on Chinese rivals under the BIOSECURE Act become visible.※ CDMO (Contract Development and Manufacturing Organization)This is a business in which a company develops and manufactures medicines on behalf of another pharmaceutical firm. As more global drugmakers choose to outsource production to specialized contractors instead of building their own plants, the market is growing rapidly, and Samsung Biologics is a leading domestic player.
\r\n\r\n◆ICTK (456010) — Hana Securities / Analyst Kim Hong-sik
- Target price: 60,000 won (raised 50% from 40,000 won) | Previous close: 36,350 won
- Investment rating: Buy (maintained)
Hana Securities raised its target price for ICTK to 60,000 won, saying the company will establish itself as a leading domestic quantum industry stock by leveraging the Trump administration's $2 billion support package for the quantum sector.
Analyst Kim Hong-sik noted that industries such as semiconductors, renewable energy, and wired optical communications, which U.S. regulators have traditionally supported, have all seen sharp stock gains. He said, "The Donald Trump administration has announced a policy to provide $2 billion in subsidies to nine quantum companies, including IBM and D-Wave, in exchange for equity participation." He added, "This policy will likely serve as a catalyst for a surge in quantum stocks."
Kim also highlighted that ICTK is the only company in South Korea to have independently developed Physical Unclonable Function (PUF) technology and that it has become the first domestic company to supply quantum security chips to a global big tech firm. He added, "It will clearly establish itself as a leading stock in the quantum industry."※ PUF (Physical Unclonable Function)This is a technology that uses the tiny physical differences each semiconductor chip acquires during manufacturing like a fingerprint to prevent forgery and tampering. Because it generates a unique identifier inside the chip each time and does not store it externally, hacking and cloning are virtually impossible. As a result, it plays a key role in the Internet of Things (IoT), smartphones, quantum security chips, and more.
\r\n\r\n
sms@fnnews.com Sung Min-seo Reporter